Warren Buffett, who is known to own “forever stocks,” has famously quipped that if you aren't willing to own a stock for 10 years, you shouldn't own it for even 10 minutes.
NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Inari Medical, Inc. ("Inari" or "the Company") (NASDAQ:NARI). Investors who purchased Inari securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NARI.
Medical Devices Industry | Healthcare Sector | Mr. Andrew J. Hykes CEO | NASDAQ (NGS) Exchange | US45332Y1091 ISIN |
US Country | 1,300 Employees | - Last Dividend | - Last Split | 22 May 2020 IPO Date |
Inari Medical, Inc. is a pioneer in the development of minimally invasive, catheter-based mechanical thrombectomy devices and accessories, aiming to revolutionize treatment in specific disease states across the United States. Initially known as Inceptus Newco1 Inc., the company rebranded to Inari Medical, Inc. in September 2013, marking a new chapter in its quest to tackle complex vascular conditions with innovative solutions. Since its foundation in 2011, and operating out of its headquarters in Irvine, California, Inari Medical has dedicated itself to serving the needs of interventional radiologists, cardiologists, and vascular surgeons through its groundbreaking products.
Designed for the effective treatment of deep vein thrombosis and peripheral thrombus, the ClotTriever system stands out for its ability to core, capture, and remove large clots from large vessels. This minimally invasive solution offers a new avenue for treating conditions that would have previously required more invasive surgical interventions.
This innovative mechanical thrombectomy system revolutionizes the treatment of pulmonary embolism and other complex venous thromboembolism cases through large bore catheter-based aspiration. The FlowTriever system is specifically engineered to remove large clots from the peripheral vasculature, offering a safer and more efficient treatment option.
Focusing on the treatment of small vessel thrombosis, the InThrill system introduces a novel approach by combining the latest advancements in catheter-based technologies. It is designed to address the challenges associated with accessing and effectively treating thrombosis in smaller vessels.
Targeting patients who suffer from chronic limb-threatening ischemia and have no suitable endovascular or surgical revascularization options, the LimFlow system presents a groundbreaking alternative. This technology potentially reduces the risk of major amputations by providing a new method for revascularizing affected limbs, transforming the treatment landscape for this debilitating condition.